摘要
肺动脉高压(PAH)是一种以肺血管阻力和肺动脉压力渐进性升高为特征,最终导致患者右心衰竭而死亡的疾病。本文综述了近年来有关PAH发生的细胞和分子机制及其治疗药物的研究进展。
Pulmonary arterial hypertension（PAH） is a pulmonary vascular resistance and pulmonary arterial ure. The mechanisms of action, approved PAH therapies were reviewed and described in this paper. progressive and fatal disease, pressure, most often resulting characterized by elevated in right-sided heart fail- and the latest agents in late-stage clinical development
出处
《中国药科大学学报》
CAS
CSCD
北大核心
2013年第1期1-10,共10页
Journal of China Pharmaceutical University
基金
国家自然科学基金资助项目(No.81072519)~~
关键词
肺动脉高压
病理特征
发生机制
分子机制
治疗药物
pulmonary arterial hypertension
pathologic features
pathogenesis
molecular mechanism
therapeu-tic drugs
